Thinking of joining a study?

Register your interest

Become a volunteer?

Clinical trials for Cancer in United States

7251 results

Sort By:

Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158)

Study ID: NCT02628067
Start Date: 2015-12-18
End Date: 2027-05-04
Study Type

Interventional

Study Phase

Phase2

No. of Participants

1609

Intervention / Treatment

pembrolizumab

pembrolizumab

Sponsor

Merck Sharp & Dohme LLC

Source: clinicaltrials.gov

Share:
Add to list

Surgical Pembro +/- Olaparib w TMZ for rGBM

Study ID: NCT05463848
Start Date: 2022-10-21
End Date: 2026-04-01
Study Type

Interventional

Study Phase

Phase2

No. of Participants

78

Intervention / Treatment

Pembrolizumab

Flapberry

Temozolomide

Sponsor

L. Nicolas Gonzalez Castro, MD, PhD

Source: clinicaltrials.gov

Share:
Add to list

Study to Evaluate Sacituzumab Govitecan in Combination With Talazoparib in Patients With Metastatic Breast Cancer.

Study ID: NCT04039230
Start Date: 2019-10-09
End Date: 2026-12
Study Type

Interventional

Study Phase

Phase2

No. of Participants

75

Intervention / Treatment

Carcolor

Sacituzumab Govitan

Sponsor

Massachusetts General Hospital

Source: clinicaltrials.gov

Share:
Add to list

Urine Methylation Markers in UTUC

Study ID: NCT06805630
Start Date: 2025-05-07
End Date: 2026-06
Study Type

Interventional

Study Phase

Not Applicable

No. of Participants

50

Intervention / Treatment

Femto Human DNA Quantification Kit

Sponsor

Duke University

Source: clinicaltrials.gov

Share:
Add to list

Combination Chemotherapy and Bevacizumab With the NovoTTF-100L(P) System in Treating Participants With Advanced, Recurrent, or Refractory Hepatic Metastatic Cancer

Study ID: NCT03203525
Start Date: 2020-06-23
End Date: 2026-12-31
Study Type

Interventional

Study Phase

Phase1

No. of Participants

52

Intervention / Treatment

Infatuating

Fluorouracil

Leucovorin

Oxaliplatin

Pegylated Liposomal Doxorubicin Hydrochloride

Tmsirolimus

Tumor Treating Fields Therapy

Sponsor

M.D. Anderson Cancer Center

Source: clinicaltrials.gov

Share:
Add to list

Gemcitabine and Ex Vivo Expanded Allogenic Universal Donor, TGFβi Natural Killer (NK) Cells with or Without Naxitamab (Danyelza) for the Treatment of Patients with Metastatic, GD2 Expressing, HER2 Negative Breast Cancer

Study ID: NCT06026657
Start Date: 2024-04-02
End Date: 2026-12-31
Study Type

Interventional

Study Phase

Phase2

No. of Participants

42

Intervention / Treatment

Biospecimen Collection

Computed Tomography

Gemcitabine

Magnetic Resonance Imaging

NAXITAMAB

Universal Donor Expanded TGF-beta-imprinted NK Cells

Sponsor

Margaret Gatti-Mays

Source: clinicaltrials.gov

Share:
Add to list

Detecting Lymph Node Metastasis in Intrahepatic Cholangiocarcinoma (LyMIC)

Study ID: NCT06381648
Start Date: 2023-04-15
End Date: 2026-06-18
Study Type

Observational

Study Phase

Not Applicable

No. of Participants

200

Intervention / Treatment

LyMIC (Lymph Node Metastasis in Intrahepatic Cholangiocarcinoma)

Sponsor

City of Hope Medical Center

Source: clinicaltrials.gov

Share:
Add to list

A Phase 1a/1b Study of ACTM-838 in Patients With Advanced Solid Tumors

Study ID: NCT06336148
Start Date: 2024-06-05
End Date: 2026-07
Study Type

Interventional

Study Phase

Phase1

No. of Participants

35

Intervention / Treatment

ACTM-838

Sponsor

Actym Therapeutics, Inc.

Source: clinicaltrials.gov

Share:
Add to list

Study of Effect of Azeliragon in Patients Refractory to Prior Treatment of Metastatic Pancreatic Cancer

Study ID: NCT05766748
Start Date: 2023-06-01
End Date: 2025-05
Study Type

Interventional

Study Phase

Phase2

No. of Participants

30

Intervention / Treatment

Azeliragon

Sponsor

Cantex Pharmaceuticals

Source: clinicaltrials.gov

Share:
Add to list

Blood Markers of Early Pancreas Cancer

Study ID: NCT03568630
Start Date: 2018-07-26
End Date: 2028-07
Study Type

Observational

Study Phase

Not Applicable

No. of Participants

1250

Intervention / Treatment
Sponsor

University of Nebraska

Source: clinicaltrials.gov

Share:
Add to list